Parkinsonian DisordersInorganic ChemicalsSupranuclear Palsy, ProgressiveMultiple System AtrophyParkinson DiseaseNeuronsParkinson Disease, SecondaryLevodopaAntiparkinson AgentsNeurons, Afferent1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineGlobus PallidusMotor NeuronsHypokinesiaMuscle RigidityBrain ChemistryBrainSubstantia NigraSubthalamic NucleusDopamineCorpus StriatumOxidopamineDopaminergic NeuronsDyskinesia, Drug-InducedBrain InjuriesBipolar DisorderBrain MappingBrain NeoplasmsTremorAction PotentialsBasal GangliaDeep Brain StimulationDyskinesiasExtrapyramidal TractsDopamine AgentsMental DisordersCarbidopaCerebral CortexMood DisordersAnxiety DisordersMovement DisordersTyrosine 3-MonooxygenaseNerve Tissue ProteinsDisease Models, AnimalOlivopontocerebellar AtrophiesBrain StemBehavior, AnimalMesencephalonHippocampusMagnetic Resonance ImagingBenserazideTime FactorsMazindolModels, NeurologicalThalamusPutamenCells, CulturedRats, Sprague-DawleyNerve DegenerationDiagnostic and Statistical Manual of Mental DisordersImmunohistochemistryMacaca fascicularisElectrophysiology